![]() |
|
|
Vol. 304, Issue 1, 464-476, January 2003
Departments of Critical Care Medicine (P.L.S., X.H., R.Y., R.L.D.,
M.P.F.), Pathology (R.L.D.) and Surgery (M.P.F.), University of
Pittsburgh Medical School, Pittsburgh, Pennsylvania
Ethyl pyruvate (EP) solution ameliorates ileal mucosal
hyperpermeability and decreases the expression of several
proinflammatory genes in ileal and/or colonic mucosa when it is used
instead of Ringer's lactate solution (RLS) to resuscitate mice from
hemorrhagic shock. To test the hypothesis that EP can ameliorate gut
barrier dysfunction induced by other forms of inflammation, we
incubated Caco-2 monolayers for 24 to 48 h with cytomix (a mixture
of interferon-
, tumor necrosis factor-
, and interleukin-1
) in
the presence or absence of graded concentrations of EP or sodium
pyruvate. Cytomix increased the permeability of Caco-2 monolayers to
fluorescein isothiocyanate-labeled dextran (FD4; average molecular mass
4 kDa), but this effect was inhibited by adding 0.1 to 10 mM EP (but
not similar concentrations of sodium pyruvate) to the culture medium.
EP inhibited several other cytomix-induced phenomena, including nuclear
factor-
B activation, inducible nitric oxide synthase mRNA
expression, and nitric oxide production. Cytomix altered the expression
and localization of the tight junctional proteins, ZO-1 and occludin,
but this effect was prevented by EP. Delayed treatment with EP solution
instead of RLS ameliorated ileal mucosal hyperpermeability to FD4 and
bacterial translocation to mesenteric lymph nodes in mice challenged
with lipopolysaccharide (LPS). These data support the view that EP
ameliorates cytokine- and/or LPS-induced derangements in intestinal
epithelial barrier function.
This article has been cited by other articles:
![]() |
C. L. Leaphart, J. Cavallo, S. C. Gribar, S. Cetin, J. Li, M. F. Branca, T. D. Dubowski, C. P. Sodhi, and D. J. Hackam A Critical Role for TLR4 in the Pathogenesis of Necrotizing Enterocolitis by Modulating Intestinal Injury and Repair J. Immunol., October 1, 2007; 179(7): 4808 - 4820. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Su, Z. Wang, Y. Cai, M. Remmelink, and J.-L. Vincent Beneficial Effects of Ethyl Pyruvate in Septic Shock From Peritonitis Arch Surg, February 1, 2007; 142(2): 166 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Han, J. A. Englert, R. Yang, R. L. Delude, and M. P. Fink Ethyl Pyruvate Inhibits Nuclear Factor-{kappa}B-Dependent Signaling by Directly Targeting p65 J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1097 - 1105. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Song, J. A. Kellum, H. Kaldas, and M. P. Fink Evidence That Glutathione Depletion Is a Mechanism Responsible for the Anti-Inflammatory Effects of Ethyl Pyruvate in Cultured Lipopolysaccharide-Stimulated RAW 264.7 Cells J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 307 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Han, T. Uchiyama, P. L. Sappington, A. Yaguchi, R. Yang, M. P. Fink, and R. L. Delude NAD+ Ameliorates Inflammation-Induced Epithelial Barrier Dysfunction in Cultured Enterocytes and Mouse Ileal Mucosa J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 443 - 449. [Abstract] [Full Text] [PDF] |
||||